Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

181.72B

Market cap181.72B

Price-Earnings ratio

23.40

Price-Earnings ratio23.40

Dividend yield

2.87%

Dividend yield2.87%

Average volume

3.01M

Average volume3.01M

High today

$337.97

High today$337.97

Low today

$333.51

Low today$333.51

Open price

$336.26

Open price$336.26

Volume

173.81K

Volume173.81K

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

The current Amgen(AMGN) stock price is $336.70, with a market capitalization of 181.72B. The stock trades at a price-to-earnings (P/E) ratio of 23.40 and offers a dividend yield of 2.9%.

On 2026-05-14, Amgen(AMGN) stock traded between a low of $333.51 and a high of $337.97. Shares are currently priced at $336.70, which is +1.0% above the low and -0.4% below the high.

The Amgen(AMGN)'s current trading volume is 173.81K, compared to an average daily volume of 3.01M.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

AMGN News

TipRanks 3h

Amgen price target lowered to $427 from $432 at Piper Sandler

Piper Sandler lowered the firm’s price target on Amgen (AMGN) to $427 from $432 and keeps an Overweight rating on the shares. Looking at the business from a hig...

Simply Wall St 13h

A Look At Amgen Valuation After Q1 Beat Guidance Upgrade And US$300 Million US Expansion

Amgen (AMGN) is back in focus after first quarter results showed higher revenue and net income versus a year earlier, along with fresh full year guidance and a...

Simply Wall St 3d

Amgen’s New Puerto Rico Biologics Investment Might Change The Case For Investing In Amgen - simplywall.st

...

Analyst ratings

49%

of 37 ratings

Buy

43.2%

Hold

48.6%

Sell

8.1%

More AMGN News

TipRanks 6d

Amgen Halts Phase 2 HZN-1116 Trial in Sjögren’s: What Investors Should Know

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.